期刊
JOURNAL OF ANTIBIOTICS
卷 64, 期 6, 页码 413-425出版社
SPRINGERNATURE
DOI: 10.1038/ja.2011.44
关键词
clinical trials; drug development; drug discovery; natural product; resistance
资金
- NHMRC [AF 511105]
The emergence of multi-drug-resistant bacteria and the lack of new antibiotics in the antibiotic drug development pipeline, especially those with new modes of action, is a major health concern. This review lists the 20 new antibiotics launched since 2000 and records the 40 compounds currently in active clinical development. Compounds in the pipeline from new antibiotic classes are reviewed in detail with reference to their development status, mode of action, spectrum of activity and lead discovery. In addition, the NP or synthetic derivation is discussed, with activity against Gram-negative bacteria highlighted. The Journal of Antibiotics (2011) 64, 413-425; doi:10.1038/ja.2011.44; published online 18 May 2011
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据